Clinical Trial

Multicenter Epidemiological Study for the Evaluation of the Seroprevalence of Total and Neutralizing Antibodies Against Adenoassociated Virus Serotypes Used in Gene Therapy in Patients With Neuromuscular Diseases of Genetic Origin.

Study acronym: SeroDysMyo
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to assess the overall seroprevalence of neutralizing antibodies against different AAVs potentially used in gene therapy in patients with genetic neuromuscular diseases.
Trial Details
NCT Number NCT07633951
Lead Sponsor Genethon
Conditions Neuromuscular Deficits, Genetic Disorder
Enrollment 450 participants
Start Date 2026-07-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-08